rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LLY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out

      Rhythm Pharma's Imcivree generated $92.1 million in Q3; its estimated $8.25 billion market cap exceeds 20 times estimated 2026 revenue. I rate RYTM stock as Hold.

      8h agoSeeking AlphaAZNRYTMLLY
      Health Canada approves Lilly's Mounjaro® (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
      9h agoYahoo FinanceLLY
      Breakingviews - COMMENTARY: Eli Lilly’s $1.4 trln valuation is heavy with hope
      22h agoReutersLLY
      Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR

      Rhythm Pharmaceuticals rose 3.6% as traders cited an alert that Eli Lilly submitted a rival bid near $150 per share plus a contingent value right.

      Nov 17Seeking AlphaRYTMLLY
      Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies
      Nov 17BenzingaLLY
      Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio
      Nov 17Yahoo FinanceLLY
      Lilly inks oncology licensing deal worth up to $5.9B with Stipple Bio

      Eli Lilly (LLY) signs an exclusive cancer-drug licensing deal with Stipple Bio for an equity investment, upfront cash, and up to $5.9B in milestones. Read more here.

      Nov 17Seeking AlphaLLY
      Eli Lilly Caught in Vendor Hack as Extortion Group Threatens to Leak Data on 1.2 Million Patients

      Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data.

      Nov 17Barron'sLLY
      Eli Lilly Third-Party Vendor Hit by Data Breach

      Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data.

      Nov 17Barron'sLLY
      Eli Lilly Short Interest Rises, Remains Below August Peak
      Nov 17BenzingaJNJLLY
      RBC Capital reiterates Eli Lilly stock rating on pipeline focus
      Nov 17Investing.comLLY
      A $1.5 Billion Reason Why Eli Lilly Stock Is in Focus
      Nov 17BarchartLLY
      Lilly agrees to acquire Calytrix Bio for $1.5bn
      Nov 17Yahoo FinanceLLY
      Was Eli Lilly Stock's 45% Run Visible Early?
      Nov 17Yahoo FinanceLLY
      Eli Lilly & Co (LLY) Receives a Buy from Barclays

      Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

      Nov 17The Globe and MailLLY
      SLS Stock Jumps After-Hours: Retail Eyes Lilly’s Cancer Deal for Valuation Clues — 2 Big Investors Grab Shares
      Nov 17Yahoo FinanceSLSLLY
      Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion
      Nov 16ReutersLLY
      Lilly signs oncology research deal with Stipple Bio worth up to $5.9 billion
      Nov 16Yahoo FinanceLLY
      Eli Lilly makes a deal outside obesity. Plus, another word of caution on Nvidia

      Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

      Nov 16CNBCNVDALLY
      Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head
      Nov 16Yahoo FinanceLLY
      Eli Lilly is trouncing Nvidia — and the weight-loss drug trade is beating AI again
      Nov 16Yahoo FinanceNVDALLY
      Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion
      Nov 16WSJLLY
      Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion As ObesityWeek Data Roll In
      Nov 16BenzingaLLY
      Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet
      Nov 16ReutersLLY
      Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion
      Nov 16BloombergLLY
      Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion

      Eli Lilly and Co (NYSE:LLY) has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash, expanding its efforts to develop treatments for rare blood disorders and strengthen its presence in haematology. Under the definitive agreement, Calytrix...

      Nov 16Yahoo FinanceLLY
      Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
      Nov 16Yahoo FinanceLLY
      Here are Monday's biggest analyst calls: Nvidia, SpaceX, CoreWeave, Tesla, Viking, Nucor, Eli Lilly & more

      Here are Monday's biggest calls on Wall Street.

      Nov 16CNBCCRWVNVDASPCXTSLALLYNUE
      Eli Lilly to buy Calytrix Bio for up to $1.5 bln
      Nov 16Investing.comLLY
      Lilly to buy Calytrix Bio for up to $1.5 billion
      Nov 16Yahoo FinanceLLY
      SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too
      Nov 16Yahoo FinanceBLKLLYMRK
      Lilly’s Zepbound shows promise in teen obesity trial (LLY:NYSE)
      Nov 15Seeking AlphaLLY
      Lilly’s Obesity Drug Zepbound Helped Adolescents Lose Weight
      Nov 15BloombergLLY
      SA Asks: What are the most attractive Big Pharma stocks right now? (LLY:NYSE)
      Nov 15Seeking AlphaLLY
      Eli Lilly Stock: What Its 23% Weight-Loss Combo and 27% Dropout Rate Mean
      Nov 15Yahoo FinanceLLY
      GLP-1s can save health system money if priced below $350 a month: analysis

      CVS Health's Aetna claims analysis finds GLP-1s priced below $350 a month could yield net savings for payors through reduced health care use. Read more here.

      Nov 14Seeking AlphaLLY
      Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
      Nov 14ReutersLLYNVO
      Lilly says its obesity drugs helped patients lose weight in clinical trials
      Nov 14ReutersLLY
      Makers of obesity drugs hit back at claims of negative side effects
      Nov 14Financial TimesLLYNVO
      What Is The Market Seeing In Eli Lilly Stock?
      Nov 14Yahoo FinanceLLY
      HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
      Nov 13Yahoo FinanceHIMSLLY
      Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years
      Nov 13BenzingaLLY
      Mapping the Market: Eli Lilly shares ready to rally again
      Nov 13ReutersLLY
      State Street Health Care SPDR (XLV) Buys $66.8 Million More Eli Lilly on Nov. 11
      Nov 13Yahoo FinanceLLYSTT
      ETFs Are Buying Eli Lilly (LLY) on Nov. 11
      Nov 13Yahoo FinanceLLY
      No more needles: Eli Lilly wins China nod for first oral GLP-1 weight-loss drug
      Nov 13South China Morning PostLLYNVO
      Eli Lilly Shoots To New High, Leads 9 To Best Stock Lists

      Top-rated Eli Lilly, known for its blockbuster GLP-1 weight loss and diabetes drugs, hit a new high and led 9 new to best stock lists.

      Nov 12Investor's Business DailyLLY
      Jefferies Raised Its Eli Lilly (LLY) Target to $1,700. Here’s What the Firm Is Counting On
      Nov 12Yahoo FinanceJEFLLY
      Eli Lilly breaks ground on $3.5B Pennsylvania manufacturing site for obesity meds

      Eli Lilly breaks ground on a $3.5B Pennsylvania manufacturing center for next-generation weight loss treatments, expected to open in 2031. Read more here.

      Nov 12Seeking AlphaLLY
      Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
      Nov 12Yahoo FinanceLLY

      This is the newest page. Registered accounts read further back.